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PO6-46 ANTIATHEROGENIC EFFECTS OF CILOSTAZOL
AND PROBUCOL ALONE, AND IN COMBINATION IN
LOW DENSITY LIPOPROTEIN
RECEPTOR-DEFICIENT MICE FED A HIGH-FAT DIET
T. Yoshikawa, K. Mitani, K. Kotosai, G. Miyakoda, Y. Yabuuchi. Free
Radical Research Institute, Otsuka Pharmaceutical Co.,Ltd., Tokushima,
771-0192, Japan
Background and aims: Cilostazol, an antiplatelet drug, and probucol, a
cholesterol-lowering drug, are reported to ameliorate atherosclerosis in ani-
mal models. However, their combined effect on atherosclerosis is unclear.
We therefore evaluated their combined effect on atherosclerotic lesions in
LDL receptor-deﬁcient mice.
Methods: Male LDL receptor-deﬁcient mice were fed a high fat diet
with or without cilostazol alone, probucol alone, or with cilostazol and
probucol in combination, for 8 weeks. Body weight and plasma lipid levels
were measured before and during treatment. At the end of treatment, the
size distribution of plasma lipoproteins was analyzed by HPLC and then
plasma HDL cholesterol levels and en face aortic atherosclerotic lesion
areas were measured.
Results: Probucol alone signiﬁcantly decreased both total cholesterol
and HDL cholesterol, while cilostazol alone did not decrease total choles-
terol but signiﬁcantly increased HDL cholesterol. Both cilostazol alone and
probucol alone signiﬁcantly decreased atherosclerotic lesion areas, and their
combined administration showed more signiﬁcant decreases than when
each drug was administered singly.
Conclusion: The combination of cilostazol and probucol was more
effective in preventing atherosclerotic lesion formation than the administra-
tion of each drug alone; this may provide us with a new strategy for treating
atherosclerosis.
PO6-47 ATHEROGENESIS, PANCREATITIS AND BRAIN
DYSFUNCTION IN LPL DEFICIENT MICE WITH
SEVERE HYPERTRIGLYCERIDEMIA
X. Zhang, R. Qi, X. Xian, Y. Wang, W. Huang, G. Liu. Institute of
Cardiovascular Sciences,Peking University, Beijing, China
Backgound and Aim: Mice of homozygous lipoprotein lipase (LPL) gene
deﬁciency could be rescued from neonatal lethality by somatic gene transfer
of a beneﬁcial mutant. These mice developed severe hypertriglyceridemia,
which mimics that of human mutations in LPL gene.
Methods and results: At age over 15 months unexpected spontaneous
atherosclerosis was detected in these mice and high levels of oxidative
products in plasma and chylomicrons (CM) were accumulated. The CM
from old mice have strong effect on activation of endothelial cells as as-
sessed by macrophage adhesion and VCAM1/MCP1 up-regulation. Similar
to LPL deﬁcient patients, these mice have increased susceptibility to acute
pancreatitis. In pancreatic acinar cells from wild type mice addition of CM
caused stimulation of amylase release, irreversible Ca2+ release and cell
damage. This effect was decreased in the presence of the lipase inhibitor
orlistat and was increased in the presence of the secretagogue CCK that
also led to generation of FFA from CM.
After discovery of learning and memory deﬁcit in these mice elec-
tron microscopy revealed the signiﬁcant decrease of pre-synaptic vesicles
in hippocampi. Furthermore, synaptophysin, one of the most important
pre-synaptic marker, also reduced signiﬁcantly.
Conclusions: The alterations in multi-organs suggested that severe HTG
might exert pathological effects via certain common mechanisms to induce
organ injury, which will provide new insights into lipid-related cellular
stress.
PO6-48 THE BIOCHEMICAL AND CARDIOVASCULAR
CONSEQUENCES OF LCAT DEFICIENCY
L. Calabresi, D. Daldassarre, E. Moleri, P. Conca, S. Castelnuovo,
G. Franceschini. Center E. Grossi Paoletti, Department of
Pharmacological Sceinces, University of Milano, Italy
We have recently identiﬁed 14 Italian families with LCAT deﬁciency,
carrying 19 different mutations in the LCAT gene. All carriers of two
mutant LCAT alleles (n=17) had remarkably low plasma HDL-C, apoA-I,
and apoA-II levels, associated with multiple alterations in HDL structure
and particle distribution, with a selective depletion of LpAI:A-II particles,
a predominance of small, pre-beta-migrating HDL and a complete lack
of HDL2. Unesteriﬁed cholesterol, the unesteriﬁed/total cholesterol ratio,
VLDL-cholesterol, and triglycerides were signiﬁcantly elevated, whereas
apoB was signiﬁcantly lower compared to controls. Twenty-three out of 44
carriers of one mutant LCAT allele (53%) had a low plasma HDL-C; the
average plasma HDL-C and apoA-I levels were signiﬁcantly lower than
in controls. Plasma LCAT activity was also signiﬁcantly lower than in
controls. Despite the atherogenic proﬁle, only one of the 17 carriers of two
mutant LCAT alleles, a 71 y.o. man with elevated LDL-C, hypertension, and
diabetes, presented with premature coronary artery disease. The evaluation
of carotid intima-media thickness (IMT) showed that carriers of two mutant
LCAT alleles have IMT values comparable to age-sex matched controls,
despite the severe hypoalphalipoproteinemia. Carriers of one mutant LCAT
allele have widely distributed IMT values, showing on average IMT values
comparable to controls. In a large series of subjects carrying mutations
in the LCAT gene, the inheritance of a mutated LCAT genotype causes
a gene-dose-dependent alteration in the plasma lipid/lipoprotein proﬁle.
No premature cardiovascular disease and no increase in carotid IMT
was observed, despite the hypoalphalipoproteinemia, in the Italian LCAT
deﬁcient subjects.
PO6-49 TRANS INTESTINAL CHOLESTEROL EFFLUX
PATHWAY IS REDUCED IN APOE KNOCKOUT MICE
C. Vrins1, A. van der Velde2, K. van den Oever2, C. Kunne2, M. van
Eck3, P. Rensen4, A. Groen1. 1Dept. of Medical Biochemistry, Academic
Medical Center, Amsterdam, The Netherlands; 2AMC Liver Center,
Academic Medical Center, Amsterdam, The Netherlands; 3Dept. of
Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden,
The Netherlands; 4Dept. Endocrinology and Metabolism, Leiden
University Medical Center, Leiden, The Netherlands
The Trans Intestinal Cholesterol Efﬂux (TICE) pathway contributes for a
substantial amount to body neutral sterol output and provides an attractive
target to increase the rate of CH excretion. In contrast to the reverse choles-
terol transport pathway via the hepatobiliary route, this pathway does not
seem to be HDL dependent based on experiments with SRB1-/- mice. Inter-
estingly, induced TICE after feeding mice either a high fat containing diet
or PPARδ agonist GW610742 correlated with elevated serum levels of LDL.
To discern whether apoE containing lipoproteins may be involved, we
intravenously injected chylomicron-mimicking TG-rich emulsion particles
containing either 3H-cholesteryl oleate (3H-CO) or cholesteryl oleyl ether
(3H-COEth), which is resistant to intracellular hydrolysis, in WT and
apoE-/- mice. Two hours after injection the proximal small intestine
(10 cm) was canulated and perfused for 90 min with buffer containing
taurocholate/lecithin (10mM:2mM).
In mice injected with 3H-COEth no radioactivity could be detected in in-
testinal mucosa and perfusate. Apparently, no direct uptake or translocation
of these injected TG-rich lipoproteins took place. In ApoE-/- mice injected
with 3H-CO, the speciﬁc CH activity in mucosa of the perfused intestine
and the perfusate was only 50% of that found in WT mice. Interestingly, in
WT mice this speciﬁc CH activity in perfusate was 4-fold higher than that
found in the mucosa of the perfused intestine suggesting highly speciﬁc
trafﬁcking of CH from serum lipoproteins across the enterocyte.
In conclusion, our data suggest that LDL is involved in the delivery of
CH and contribute to the rate of TICE.
PO6-50 RECOMBINANT PAF-ACETYLHYDROLASE
ENHANCES THE CHOLESTEROL EFFLUX FROM
MACROPHAGES INDUCED BY RECONSTITUTED
HIGH DENSITY LIPOPROTEIN OR
APOLIPOPROTEIN A-I
M.P. Petraki1 , A. Chroni2, A.D. Tselepis1. 1Department of Chemistry,
University of Ioannina, 45110 Ioannina, Greece; 2National Centre of
Scientiﬁc Research
Background and aim: High-density lipoprotein (HDL) exhibits important
antiatherogenic activities, however the role of each HDL component in its
biological effects remains to be established. One of the HDL components
is platelet-activating factor acetylhydrolase (PAF-AH), alternatively named
as lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that
degrades PAF and oxidized phospholipids. We studied the possible role
of recombinant PAF-AH (rPAF-AH) on cholesterol efﬂux induced by
apolipoprotein A-I (apoA-I) or reconstituted HDL particles (recHDL) in
mouse J774 macrophages.
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